Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats

Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are antihyperglycemic agents with cardioprotective properties against diabetic cardiomyopathy (DCM). However, the distinctive mechanisms underlying GLP-1RAs and SGLT2is in DCM are not fully e...

Full description

Bibliographic Details
Main Authors: Nguyen Ngoc Trang, Cheng-Chih Chung, Ting-Wei Lee, Wan-Li Cheng, Yu-Hsun Kao, Shih-Yu Huang, Ting-I Lee, Yi-Jen Chen
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:International Journal of Molecular Sciences
Subjects:
diabetic cardiomyopathy
glucagon-like peptide 1 receptor agonists
liraglutide
sodium-glucose cotransporter-2 inhibitors
empagliflozin
fatty acid and glucose metabolism
Online Access:https://www.mdpi.com/1422-0067/22/3/1177

Internet

https://www.mdpi.com/1422-0067/22/3/1177

Similar Items